444 related articles for article (PubMed ID: 28607401)
1. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.
Hsu KC; Liu CY; Lin TE; Hsieh JH; Sung TY; Tseng HJ; Yang JM; Huang WJ
Sci Rep; 2017 Jun; 7(1):3228. PubMed ID: 28607401
[TBL] [Abstract][Full Text] [Related]
2. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
3. Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations.
Kollar J; Frecer V
J Mol Graph Model; 2018 Oct; 85():97-110. PubMed ID: 30145395
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
Bürli RW; Luckhurst CA; Aziz O; Matthews KL; Yates D; Lyons KA; Beconi M; McAllister G; Breccia P; Stott AJ; Penrose SD; Wall M; Lamers M; Leonard P; Müller I; Richardson CM; Jarvis R; Stones L; Hughes S; Wishart G; Haughan AF; O'Connell C; Mead T; McNeil H; Vann J; Mangette J; Maillard M; Beaumont V; Munoz-Sanjuan I; Dominguez C
J Med Chem; 2013 Dec; 56(24):9934-54. PubMed ID: 24261862
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Uba AI; Yelekçi K
J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
7. A Fluorescence-Lifetime-Based Binding Assay for Class IIa Histone Deacetylases.
Meyners C; Mertens M; Wessig P; Meyer-Almes FJ
Chemistry; 2017 Mar; 23(13):3107-3116. PubMed ID: 27922200
[TBL] [Abstract][Full Text] [Related]
8. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.
Lobera M; Madauss KP; Pohlhaus DT; Wright QG; Trocha M; Schmidt DR; Baloglu E; Trump RP; Head MS; Hofmann GA; Murray-Thompson M; Schwartz B; Chakravorty S; Wu Z; Mander PK; Kruidenier L; Reid RA; Burkhart W; Turunen BJ; Rong JX; Wagner C; Moyer MB; Wells C; Hong X; Moore JT; Williams JD; Soler D; Ghosh S; Nolan MA
Nat Chem Biol; 2013 May; 9(5):319-25. PubMed ID: 23524983
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel potential scaffold for class I HDACs inhibition: An in-silico protocol based on virtual screening, molecular dynamics, mathematical analysis and machine learning.
Fan C; Huang Y
Biochem Biophys Res Commun; 2017 Sep; 491(3):800-806. PubMed ID: 28705738
[TBL] [Abstract][Full Text] [Related]
10. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
11. Virtual screening and experimental validation of novel histone deacetylase inhibitors.
Huang YX; Zhao J; Song QH; Zheng LH; Fan C; Liu TT; Bao YL; Sun LG; Zhang LB; Li YX
BMC Pharmacol Toxicol; 2016 Jul; 17(1):32. PubMed ID: 27443303
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
Luckhurst CA; Aziz O; Beaumont V; Bürli RW; Breccia P; Maillard MC; Haughan AF; Lamers M; Leonard P; Matthews KL; Raphy G; Stott AJ; Munoz-Sanjuan I; Thomas B; Wall M; Wishart G; Yates D; Dominguez C
Bioorg Med Chem Lett; 2019 Jan; 29(1):83-88. PubMed ID: 30463802
[TBL] [Abstract][Full Text] [Related]
13. Structure-based virtual screening for novel potential selective inhibitors of class IIa histone deacetylases for cancer treatment.
Elmezayen AD; Kemal Y
Comput Biol Chem; 2021 Jun; 92():107491. PubMed ID: 33930743
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
Gupta R; Ambasta RK; Kumar P
Life Sci; 2020 Sep; 256():117912. PubMed ID: 32504755
[TBL] [Abstract][Full Text] [Related]
15. Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
Botta CB; Cabri W; Cini E; De Cesare L; Fattorusso C; Giannini G; Persico M; Petrella A; Rondinelli F; Rodriquez M; Russo A; Taddei M
J Med Chem; 2011 Apr; 54(7):2165-82. PubMed ID: 21417297
[TBL] [Abstract][Full Text] [Related]
16. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
17. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
Christianson DW
Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylases: structural determinants of inhibitor selectivity.
Micelli C; Rastelli G
Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y; Li H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
[TBL] [Abstract][Full Text] [Related]
20. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
Kee HJ; Kim I; Jeong MH
Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
